Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Real-world data show mobocertinib is effective for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Patients experienced a median progression-free survival of 4.76 months and overall survival of 26.28 months.
Area Of Science
- Oncology
- Pharmacology
- Clinical Research
Background
- Limited real-world data exist for mobocertinib in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion (ex20ins) mutations.
- This study aims to describe the characteristics and outcomes of these patients treated with mobocertinib.
Purpose Of The Study
- To evaluate the real-world effectiveness and safety of mobocertinib in NSCLC patients with EGFR ex20ins mutations.
- To analyze patient demographics, clinical parameters, treatment patterns, and outcomes, including progression-free survival (PFS) and overall survival (OS).
Main Methods
- A retrospective chart review was conducted across Canada, France, and Hong Kong.
- Included patients (NCT05207423) were diagnosed with stage IIIB-IV NSCLC with EGFR ex20ins, aged ≥18 years, and received mobocertinib between January 1, 2017, and November 30, 2021.
- Data collected included demographics, clinical parameters, treatment, mobocertinib exposure, outcomes, and adverse events (AEs), with results stratified by race.
Main Results
- 105 patients were enrolled; most received mobocertinib in second or third-line therapy.
- Median real-world PFS was 4.76 months, overall response rate was 20.0%, and median OS was 26.28 months.
- The most common AE was diarrhea (49.5%); 69.5% of patients experienced any AE. Asian patients showed numerically superior PFS and OS.
Conclusions
- Mobocertinib demonstrates real-world effectiveness in NSCLC patients with EGFR ex20ins mutations.
- The safety profile is consistent with known AEs, with diarrhea being the most frequent.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...